Literature DB >> 7513441

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

A L Cox1, J Skipper, Y Chen, R A Henderson, T L Darrow, J Shabanowitz, V H Engelhard, D F Hunt, C L Slingluff.   

Abstract

Of several thousand peptides presented by the major histocompatibility molecule HLA-A2.1, at least nine are recognized by melanoma-specific cytotoxic T lymphocytes (CTLs). Tandem mass spectrometry was used to identify and to sequence one of these peptide epitopes. Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested. Recognition by multiple CTL lines suggests that this may be a promising candidate for use in peptide-based melanoma vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513441     DOI: 10.1126/science.7513441

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  164 in total

Review 1.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

2.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.

Authors:  Philipp Beckhove; Rolf Warta; Britt Lemke; Diana Stoycheva; Frank Momburg; Martina Schnölzer; Uwe Warnken; Hubertus Schmitz-Winnenthal; Rezvan Ahmadi; Gerhard Dyckhoff; Mariana Bucur; Simone Jünger; Thomas Schueler; Volker Lennerz; Thomas Woelfel; Andreas Unterberg; Christel Herold-Mende
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

4.  Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis.

Authors:  R C Hendrickson; J F Douglass; L D Reynolds; P D McNeill; D Carter; S G Reed; R L Houghton
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 5.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

6.  Large-scale analysis of HLA peptides presented by HLA-Cw4.

Authors:  Samuel Buchsbaum; Eilon Barnea; Lior Dassau; Ilan Beer; Elena Milner; Arie Admon
Journal:  Immunogenetics       Date:  2003-05-16       Impact factor: 2.846

Review 7.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

8.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

9.  Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17.

Authors:  B S Kwon; R Halaban; S Ponnazhagan; K Kim; C Chintamaneni; D Bennett; R T Pickard
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

10.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

Authors:  S J Orlow; V J Hearing; C Sakai; K Urabe; B K Zhou; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.